HK1100814A1 - Use of non-sedating barbiturate compounds in preparation of neuroprotective agents - Google Patents

Use of non-sedating barbiturate compounds in preparation of neuroprotective agents

Info

Publication number
HK1100814A1
HK1100814A1 HK07105924.3A HK07105924A HK1100814A1 HK 1100814 A1 HK1100814 A1 HK 1100814A1 HK 07105924 A HK07105924 A HK 07105924A HK 1100814 A1 HK1100814 A1 HK 1100814A1
Authority
HK
Hong Kong
Prior art keywords
preparation
neuroprotective agents
sedative
sedating barbiturate
barbiturate compounds
Prior art date
Application number
HK07105924.3A
Other languages
English (en)
Inventor
Daniel A Moros
Barrie Levitt
Avraham Yacobi
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of HK1100814A1 publication Critical patent/HK1100814A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK07105924.3A 2000-07-26 2007-06-05 Use of non-sedating barbiturate compounds in preparation of neuroprotective agents HK1100814A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22167200P 2000-07-26 2000-07-26

Publications (1)

Publication Number Publication Date
HK1100814A1 true HK1100814A1 (en) 2007-09-28

Family

ID=22828824

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105924.3A HK1100814A1 (en) 2000-07-26 2007-06-05 Use of non-sedating barbiturate compounds in preparation of neuroprotective agents

Country Status (14)

Country Link
EP (1) EP1311270B1 (xx)
JP (1) JP5047442B2 (xx)
CN (2) CN100522172C (xx)
AT (1) ATE383159T1 (xx)
AU (2) AU2001280778B2 (xx)
BR (1) BR0112775A (xx)
CA (1) CA2416535C (xx)
DE (1) DE60132337T2 (xx)
ES (1) ES2300349T3 (xx)
HK (1) HK1100814A1 (xx)
IL (3) IL154060A0 (xx)
MX (1) MXPA03000824A (xx)
PT (1) PT1311270E (xx)
WO (1) WO2002007729A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
AU2001280778B2 (en) * 2000-07-26 2004-09-02 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
WO2003063872A1 (en) * 2002-01-30 2003-08-07 Taro Pharmaceutical Industries Ltd. Non-sedating barbituric acid derivatives
WO2004032858A2 (en) 2002-10-11 2004-04-22 Baxter International, Inc. Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
BR0317289A (pt) * 2002-12-11 2005-11-08 Taro Pharma Ind Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
EP2755945A1 (en) * 2011-09-12 2014-07-23 Council of Scientific & Industrial Research ARYLATED beta-DICARBONYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
WO2017112025A2 (en) 2015-10-05 2017-06-29 The University Of North Carolina At Chapel Hill Decoding methods for multiplexing assays and associated fluidic devices, kits, and solid supports

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
AU2001280778B2 (en) * 2000-07-26 2004-09-02 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Also Published As

Publication number Publication date
IL154060A (en) 2013-05-30
EP1311270A1 (en) 2003-05-21
CN1461219A (zh) 2003-12-10
AU8077801A (en) 2002-02-05
CN1329032C (zh) 2007-08-01
WO2002007729A9 (en) 2002-08-08
BR0112775A (pt) 2003-12-30
JP2004517808A (ja) 2004-06-17
CA2416535C (en) 2010-11-16
EP1311270B1 (en) 2008-01-09
IL165017A0 (en) 2005-12-18
ATE383159T1 (de) 2008-01-15
AU2001280778B2 (en) 2004-09-02
JP5047442B2 (ja) 2012-10-10
WO2002007729A1 (en) 2002-01-31
CN1872067A (zh) 2006-12-06
DE60132337T2 (de) 2009-02-12
IL154060A0 (en) 2003-07-31
CA2416535A1 (en) 2002-01-31
PT1311270E (pt) 2008-04-15
DE60132337D1 (de) 2008-02-21
EP1311270A4 (en) 2006-04-12
ES2300349T3 (es) 2008-06-16
CN100522172C (zh) 2009-08-05
MXPA03000824A (es) 2004-11-01

Similar Documents

Publication Publication Date Title
HK1100814A1 (en) Use of non-sedating barbiturate compounds in preparation of neuroprotective agents
AU7315301A (en) Compounds and compositions for delivering active agents
MXPA02007690A (es) Composiciones de liberacion controlada que contienen agonista y antiagonista de opioide.
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
HUP0302792A3 (en) Cyclopropyl-fused pyrrolidine-based onhibitors of dipeptidyl peptidase iv and method for their preparation and pharmaceutical compositions containing the compounds
PL347671A1 (en) Compounds and compositions for delivering active agents
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
IL149147A0 (en) Use of oxcarbazepine for the manufacture of oral dosage form medicament
IL195055A0 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
AU3492100A (en) Oxadiazole compounds and compositions for delivering active agents
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
MY153713A (en) A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate
AP2003002763A0 (en) Controlled release formulations for oral administration
MY124727A (en) Tri-substituted phenyl derivatives and analogues.
GR3020330T3 (en) Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds.
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
EP1905441A3 (en) Non-sedating barbiturate compounds as neuroprotective agents
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
DE60112584D1 (de) Verfahren zur Herstellung einer flüssigen Dosierungseinheit und Kit
CO5580753A2 (es) Composicion farmaceutica que comprende un antagonista ltb4 y un inhibidor cox-2 o un inhibidor cox1/2
MY145885A (en) Controlled release formulations for oral administration
DE50311479D1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE ENGLISH TITLE OF INVENTION FROM USE OF NONSEDATING BARBITURATE COMPOUNDS IN PREPARATION OF NEUROPROTECTIVE AGENTS TO USE OF A SALT OF DIPHENYL BARBITURIC ACID IN PREPARING NEUROPROTECTIVE AGENTS